Bayer Partners With Emirates Societies To Improve Allergic Rhinitis Management In The Region

In an effort to combat the widespread issue of allergic rhinitis in the region, which affects up to 45% of the population, hindering their daily quality of life and productivity, Bayer has taken a significant step forward. The company has announced its collaboration with the Emirates ENT Society and the Emirates Pharmacists Society. This partnership aims to bridge the gap between medical expertise and innovative healthcare solutions, thereby enhancing the management of allergic rhinitis.

The announcement was made at a regional allergy awareness media roundtable in Dubai, setting the stage for the upcoming introduction of ClariSpray, a new product designed to offer relief to those suffering from this condition. Bayer's initiative reflects its commitment to scientific excellence and providing patient-centric solutions aimed at improving the well-being of individuals afflicted by allergies.

Dr. Mohammed Ahmed Abdulla Al Hammadi, Vice President of the Emirates ENT Society, emphasized the importance of collaboration between the medical sector and specialised healthcare partners. He highlighted that the partnership with Bayer presents an unparalleled opportunity to combine Bayer's services and solutions with the medical society's clinical experience. The goal is to enhance the treatment of allergies and secure the best medical outcomes for patients across the region.

Dr. Abdulla Al Kindi, Head of the Emirates Pharmacists Society, also voiced support for this collaborative effort. He stated, "To better serve allergic rhinitis sufferers in our region, the Emirates Pharmacists Society recognizes these partnerships as essential." This synergy is expected to lead to significant improvements in patient care and well-being, by addressing their specific needs more effectively.

Dr. Mohammad Galal, Vice President, Head of Middle East & Pakistan at Bayer Consumer Health, outlined the company's focus on enabling individuals to manage their health proactively. "The launch of ClariSpray, coupled with these vital partnerships with leading medical societies across the GCC and Emirates, underscores our deep commitment to addressing the significant burden of allergic rhinitis in this region," he noted. By collaborating closely with healthcare professionals, Bayer aims to raise awareness, enhance access to innovative solutions, and improve the lives of those affected by allergies.

The collaboration between Bayer and the medical societies is set to deepen the understanding of regional allergy needs, facilitate the creation of tailored solutions, and improve patient access to quality care and information. It also aims to bolster the capability of healthcare professionals in managing allergic rhinitis, marking a significant step toward better health outcomes.

The partnership between Bayer, the Emirates ENT Society, and the Emirates Pharmacists Society represents a strategic move to enhance the management of allergic rhinitis in the region. With the introduction of ClariSpray and the combined expertise of medical professionals and Bayer's commitment to healthcare innovation, this collaborative effort is poised to bring about meaningful improvements in the care and quality of life of individuals suffering from allergies.